



# Regional Medicines Optimisation Committee

## Medicines Optimisation Prioritisation Panel Minutes



Wednesday 16th January 2019

107D Skipton House, 80 London Road, London and via  
teleconference

2.00pm - 4.30pm

### Present:

Name	Title	Organisation	RMOC
Steve Brown (SB) <i>Vice Chair</i>	Regional Pharmacist (South)	NHS England / NHS Improvement	South
Michele Cossey (MC)	Regional Pharmacist ( North)	NHS England / NHS Improvement	North
Richard Goodman (RG)	Regional Pharmacist (London)	NHS England / NHS Improvement	London
Liz Kay (LK)	Professor of Pharmaceutical Care / Clinical Director	Leeds Teaching Hospitals NHS Trust	North
Dr John Reynolds (JR)	Consultant General Physician and Clinical Pharmacologist	The Oxford University Hospitals NHS Foundation Trust	South
Carol Roberts (CR)	Chief Executive	PrescQIPP CIC	
Richard Seal (RS)	Regional Pharmacist (Midlands & East)	NHS England / NHS Improvement	Midlands & East
Devika Sennik (DS)	Lead Pharmacist South East London Area Prescribing Committee	South East London Area Prescribing Committee	London
Phillip Thomas (PT)	Medicines Optimisation Delivery Lead	Medicines and Diagnostics Policy Unit, NHS England	
<b>SPS Support Staff (Non-Voting)</b>			
Sue Dickinson (Professional Secretary) (SD)	Director of Pharmacy	Regional Drug and Therapeutics Centre (Newcastle)	
Helen Davis (HD)	Director	North West Medicines Information Centre	

### Apologies:

Name	Title	Organisation	Comments sent?
Dr Keith Ridge (KR) <i>Chair</i>	Chief Pharmaceutical Officer	NHS England	N
Malcolm Qualie (MQ)	Pharmacy Lead	Specialised Commissioning. NHS England	N
Dr Shaun O'Connell (SO'C)	GP Lead for Acute Service Transformation	NHS Vale of York CCG	Y

Gillian Adams (GA)	Lay Member  Public / patient member	NHS West Leicestershire Clinical Commissioning Group Governing body  NHSE Clinical Reference Group for Blood and Marrow Transplantation	Y
Alex Williams (AW)	Deputy Director	Medicines and Diagnostics Policy Unit, NHS England	N

**In attendance:**

Justine Scanlan (JS), Head of the Specialist Pharmacy Service, NHS England, Ben Rehman (BR), Assistant Head (Medicines Optimisation), NHS Specialist Pharmacy Service, Ashley Marsden, Medicines Optimisation Lead Medicines Information North West, Samrina Bhatti, Chief Pharmaceutical Officer's Clinical Fellow (SPS). DS was present for the first half of the meeting and provided comments covering the remaining agenda items.

**Declarations of Interest**

In relation to MO topics to be discussed SB had submitted agenda items 7.6 and 7.7. No other declarations of interest were made or had been submitted. All members have provided or updated existing Declarations of Interest held as part of ongoing Regional Medicines Optimisation Committee (RMOC) membership. All members have signed confidentiality agreements relating to information provided as part of the prioritisation decision making papers. Annual declarations were due for renewal; SD would send out form for completion in advance of the March meeting.

**1. Welcome and Introductions**

SB in the role of Chair welcomed members to the eighth meeting of the Medicines Optimisation Prioritisation Panel.

**2. Minutes of the meeting held on 7<sup>th</sup> November 2018**

Draft minutes were presented and with one amendment were accepted as a true record.

**3. Review of previous actions**

Members were provided with an update on progress against actions previously discussed from earlier meetings. These were noted and items closed where agreed.

**4. Feedback from December 2018 MOOG**

SB and PT provided feedback from the last MOOG meeting held in December 2018. The draft Operating Model was undergoing a further rewrite to clarify some process around RMOC consideration and recommendation. Project support for RMOCs had been approved from CSUs in work areas including APC liaison.

## 5. RMOC / PresQIPP liaison

Action to ensure work plans are shared at an early stage across RMOC and larger APCs / Medicines Optimisation Groups will be undertaken. Ambition is to have RMOC as standing agenda items for all such groups.

## 6. Medicines Optimisation Topics submitted

A review of all Medicines Optimisation topics and MOPP decisions to date was carried out.

## 7. Medicines Optimisation Topics submitted

Topics submitted and /or triaged since the last MOPP meeting in November 2018 were considered by the panel.

Topic title	Date submitted	MOPP recommendation
7.1 Eflornithine for use in transgender patients	15/8/18	For RMOC consideration
7.2 Formulary application information for biosimilar adalimumab	20/8/18	Not RMOC
7.3 Rivaroxaban 2.5mg for prevention of thrombotic events in CAD or PAD	29/8/18	For RMOC consideration
7.4 Use of Jorveza for treating active eosinophilic oesophagitis	10/9/18	For RMOC consideration
7.5 Hydrocortisone granules in capsules for opening (Alkindi)	13/9/18	For RMOC consideration
7.6 Biosimilar insulin guidance	17/9/18	For RMOC as part of biosimilars workstream
7.7 Biosimilar to biosimilar switching	8/10/18	Not RMOC
7.8 Prescribing by private providers (to include online GP services)	31/12/18	NOT for RMOC
7.9 Xonvea – doxylamine succinate and pyridoxine hydrochloride		Not discussed as already in new medicines work stream

## 8. New medicines indications for prioritisation

Doxalymine / pyridoxine, melatonin and inhaled levodopa are confirmed on the new medicines work plan.

Prioritisation for 2019 / 20 will take place in March 2019.

**9. AOB:**

Communication of RMOC activity and the introduction of a new communication tool highlighted.

**10. Date of next meeting: Tuesday 5<sup>th</sup> March 2019, 10.00am – 12.00pm, Skipton House and via teleconference**